Open Clinical Trials for Metastatic Breast Cancer in Canada

Use our blog on Understanding Common Research Terms as a guide for some of the terms we reference.

December 2024

A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)

Summary: The goal of this clinical trial is to see how well the drug DB-1303/BNT323 works compared to standard chemotherapy. The main focus is on how long people live without their cancer getting worse (progression free survival) for individuals with HR+, HER2-low breast cancer, which includes two specific subtypes: IHC 2+/ISH- and IHC 1+.

Patient Population: HR+, HER2-low (IHC 1+ or IHC 2+/ISH-) Metastatic Breast Cancer

Locations: Brampton, ON; Toronto, ON; Montreal, QC; Sherbrooke, QC

Learn more

A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer

Summary: The goal of this study is to see how well the drug inavolisib works in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with previously untreated HER2+ mBC.

Patient Population: PIK3CA mutated HER2+ Metastatic Breast Cancer

Locations: Calgary, AB; Moncton, NB; St. John's, NL; Montreal, QC; Quebec City, QC; Regina, SK

Learn more

A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

Summary: The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer whose disease has progressed after prior CDK 4/6 inhibitor therapy

Patient Population: HR+, HER2- Metastatic Breast Cancer who have progressed on CDK 4/6 inhibitor

Locations: Fredericton, NB; Sydney, NS; Barrie, ON; Brampton, ON; Oakville, ON; Chicoutimi, QC; Montreal, QC; Quebec City, QC

Learn more

Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Summary: This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments?

Patient Population: CDK4/6-inhibitor Resistant ER+, HER2- Metastatic Breast Cancer

Locations: Calgary, AB; Kelowna, BC; Vancouver, BC; Halifax, NS; Hamilton, ON; Kingston, ON; Ottawa, ON; Toronto, ON; Montreal; QC

Learn more

OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01)

Summary: This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.

Patient Population: ER+, HER2- Metastatic Breast Cancer patients who have previously received CDK 4/6 inhibitor

Locations: Calgary, AB; Montreal, QC

Learn more

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Summary: This Phase III study investigates the efficacy and safety of Dato-DXd with or without durvalumab compared with standard chemotherapy in combination with pembrolizumab in patients with PD-L1+ metastatic TNBC

Patient Population: PD-L1+ inoperable or Metastatic Triple Negative Breast Cancer with no prior metastatic treatment

Locations: Barrie, ON; Hamilton, ON; Toronto, ON; Greenfield Park, QC; Montreal, QC; Regina, SK; Saskatoon, SK

Learn more

Ten Patient Pilot Study to Evaluate Safety of the ZetaFuse™ Bone Graft Administered Using an Outpatient Local Intratumoral Injection Procedure to Treat Breast Cancer Bone Metastases in the Spine to Control Pain and Prevent Complications Such as Fracture (ZGMBC)

Summary: The ZetaFuse™ Bone Graft is indicated for patients with destructive, lytic lesions due to metastatic breast cancer to bone, with or without involvement of other sites, with at least one metastatic lesion located in a vertebral body of the spine, and a Spinal Instability Neoplastic Score (SINS) ≥3 and ≤9. The ZetaFuse™ Bone Graft is percutaneously implanted into the bone defect created by the metastatic tumor in a spinal vertebral body. The ZetaFuse™ Bone Graft is only for implantation into the vertebral body.

Patient Population: Metastatic Breast Cancer to the bone, with or without involvement of other sites; at least one lytic metastatic lesion located in the vertebral body of the spine

Locations: Vancouver, BC; Montreal, QC

Learn more

**Development of this issue of Clinical Trials Connected has been made possible through financial contributions from Novartis and Gilead.*